Piperidine urea derivatives as soluble epoxide hydrolase inhibitors

A method for treatment of pain, neuro degenerative disease, or inflammatory disease in a subject, the method comprising administering to the subject a therapeutically effective amount of at least one compound of Formula I:

• its stereoisomers or pharmaceutically acceptable salts thereof wherein;
• R1 is selected from a group consisting of alkyl, hydrogen, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl and wherein when R1 is aryl, heteroaryl or heterocycloalkyl, R1 is unsubstituted or substituted with alkyl, hydroxy, halogen, haloalkyl, hydroxyalkyl, alkoxyalkyl, alkoxy, amine, SO2R5, SO2NHR2, or COR3;
• R2 is selected from a group consisting of hydrogen, alkyl, haloalkyl, or cycloalkyl;
• R3 is selected from a group consisting of alkyl, cycloalkyl, hydroxy, amine, alkyamine or alkoxy;
• R4 is selected from a group consisting of hydrogen, alkyl, halogen, haloalkyl, hydroxy, amine, alkoxy, SO2R6, SO2NHR2, or COR3;
• R5 is selected from a group consisting of alkyl, haloalkyl, cycloalkyl, aryl or amine;
• R6 is selected from a group consisting of alkyl, cycloalkyl, aryl or heteroaryl, aryl or heteroaryl may optionally be substituted one or more times with groups or substituents such as alkyl, hydroxy, halogen, haloalkyl;
• X is selected from O, (CH2)p, NH and p is from 0-2, however when p=0, Y1-Y2 is not CH—CH2 or CH—O, and R1 is not aryl;
• Y1-Y2 are selected from CH—CH2, CH—O, or C═CH, however when Y1-Y2 is CH—O, X is selected from O or NH, and R1 is not hydrogen, or alkyl;
• and
• Y3 is selected from H or Me.